Amendments to the Claims:

Please amend Claims 25, 34, 41, 49, 54, 64 and 74 as set forth below, and cancel Claims 37, 38, 50, 51 and 61 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

1-24. (Canceled)

25. (Currently Amended) A therapeutic product obtained from cord blood or placental blood, wherein the therapeutic product comprises white blood cells, less than all of plasma contained in said cord blood or placental blood, less than all of red blood cells contained in said cord blood or placental blood, and a cryoprotective agent, wherein the therapeutic product is characterized by a white cell viability greater than 80% ~~with respect to said cord blood or placental blood~~.

26. (Canceled)

27. (Previously presented) The therapeutic product of Claim 25, wherein said cryoprotective agent comprises dimethyl sulfoxide.

28. (Previously presented) The therapeutic product of Claim 25, wherein said cryoprotective agent comprises dextran.

29. (Previously presented) The therapeutic product of Claim 27, wherein said dimethyl sulfoxide is diluted to 50% with dextran.

30. (Previously presented) The therapeutic product of Claim 27, wherein a concentration of said dimethyl sulfoxide is not greater than 10%.

31. (Previously presented) The therapeutic product of Claim 27, wherein a concentration of said dimethyl sulfoxide is not greater than 1%.

32. (Previously presented) The therapeutic product of Claim 27, wherein an osmolarity of said product is not more than 300 milliosmols.

33. (Previously presented) The therapeutic product of Claim 25, wherein the therapeutic product contains less than 10% of red blood cells contained in said cord blood or placental blood.

34. (Currently amended) The therapeutic product of Claim 25, wherein the therapeutic product is characterized by a white cell viability greater than 90% ~~with respect to said cord blood or placental blood~~.

35. (Previously presented) The therapeutic product of Claim 25, wherein the therapeutic product comprises an anticoagulant.

36. (Previously presented) The therapeutic product of Claim 35, wherein the anticoagulant is Citrate, Phosphate, and Dextrose.

37-38. (Canceled)

39. (Previously presented) The therapeutic product of Claim 25, wherein white cell viability is tested using DNA fluorescence stain.

40. (Previously presented) The therapeutic product of Claim 25, wherein the therapeutic product is contained in a volume of 3 milliliters to 20 milliliters.

41. (Currently amended) A therapeutic product obtained from cord blood or placental blood, wherein the therapeutic product consists essentially of white blood cells, less than all of plasma contained in said cord blood or placental blood, less than all of red blood cells contained in said cord blood or placental blood, and a cryoprotective agent, wherein the therapeutic product is characterized by a white cell viability greater than 80% ~~with respect to said cord blood or placental blood~~.

42. (Previously presented) The therapeutic product of Claim 41, wherein said cryoprotective agent comprises dimethyl sulfoxide.

43. (Previously presented) The therapeutic product of Claim 41, wherein said cryoprotective agent comprises dextran.

44. (Previously presented) The therapeutic product of Claim 42, wherein said dimethyl sulfoxide is diluted to 50% with dextran.

45. (Previously presented) The therapeutic product of Claim 42, wherein a concentration of said dimethyl sulfoxide is not greater than 10%.

46. (Previously presented) The therapeutic product of Claim 42, wherein a concentration of said dimethyl sulfoxide is not greater than 1%.

47. (Previously presented) The therapeutic product of Claim 42, wherein an osmolarity of said product is not more than 300 milliosmols.

48. (Previously presented) The therapeutic product of Claim 41, wherein the therapeutic product contains less than 10% of red blood cells contained in said cord blood or placental blood.

49. (Currently amended) The therapeutic product of Claim 41, wherein the therapeutic product is characterized by a white cell viability greater than 90% ~~with respect to said cord blood or placental blood~~.

50-51. (Canceled)

52. (Previously presented) The therapeutic product of Claim 41, wherein white cell viability is tested using DNA fluorescence stain.

53. (Previously presented) The therapeutic product of Claim 41, wherein the therapeutic product is contained in a volume of 3 milliliters to 20 milliliters.

54. (Currently amended) A therapeutic product obtained from cord blood or placental blood, wherein the therapeutic product consists essentially of white blood cells, less than 10% of red blood cells contained in said cord blood or placental blood, less than all of plasma contained in said cord blood or placental blood, and a cryoprotective

agent, wherein the therapeutic product is characterized by a white cell viability greater than 90% ~~with respect to said cord blood or placental blood~~.

55. (Previously presented) The therapeutic product of Claim 54, wherein said cryoprotective agent comprises dimethyl sulfoxide.

56. (Previously presented) The therapeutic product of Claim 54, wherein said cryoprotective agent comprises dextran.

57. (Previously presented) The therapeutic product of Claim 55, wherein said dimethyl sulfoxide is diluted to 50% with dextran.

58. (Previously presented) The therapeutic product of Claim 55, wherein a concentration of said dimethyl sulfoxide is not greater than 10%.

59. (Previously presented) The therapeutic product of Claim 55, wherein a concentration of said dimethyl sulfoxide is not greater than 1%.

60. (Previously presented) The therapeutic product of Claim 55, wherein an osmolarity of said product is not more than 300 milliosmols.

61. (Canceled)

62. (Previously presented) The therapeutic product of Claim 54, wherein white cell viability is tested using DNA fluorescence stain.

63. (Previously presented) The therapeutic product of Claim 54, wherein the therapeutic product is contained in a volume of 3 milliliters to 20 milliliters.

64. (Currently amended) A therapeutic product obtained from cord blood or placental blood, wherein the therapeutic product consists essentially of ~~at least 80% of~~ white blood cells having a viability greater than 80%, ~~from said cord blood or placental blood with viability greater than 90%, fewer than 10% of red blood cells contained in said cord blood or placental blood, less than all of plasma contained in said cord blood or placental blood,~~ and a cryoprotective agent.

65. (Previously presented) The therapeutic product of Claim 64, wherein said cryoprotective agent comprises dimethyl sulfoxide.

66. (Previously presented) The therapeutic product of Claim 64, wherein said cryoprotective agent comprises dextran.

67. (Previously presented) The therapeutic product of Claim 65, wherein said dimethyl sulfoxide is diluted to 50% with dextran.

68. (Previously presented) The therapeutic product of Claim 65, wherein a concentration of said dimethyl sulfoxide is not greater than 10%.

69. (Previously presented) The therapeutic product of Claim 65, wherein a concentration of said dimethyl sulfoxide is not greater than 1%.

70. (Previously presented) The therapeutic product of Claim 65, wherein an osmolarity of said product is not more than 300 milliosmols.

71. (Previously presented) The therapeutic product of Claim 64, wherein white cell viability is tested using DNA fluorescence stain.

72. (Previously presented) The therapeutic product of Claim 64, wherein the therapeutic product is contained in a volume of 3 milliliters to 20 milliliters.

73. (Currently amended) The therapeutic product of Claim 64, wherein the therapeutic product has ~~is characterized by~~ a white cell viability greater than 90% ~~after freezing and thawing of the therapeutic product~~.